Adefovir dipivoxil/lamivudine

Drug Profile

Adefovir dipivoxil/lamivudine

Alternative Names: Lamivudine/adefovir dipivoxil

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purine nucleotides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Immunomodulators; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Hong Kong (PO, Capsule)
  • 30 Apr 2011 GlaxoSmithKline completes a phase I trial in Chronic Hepatitis B in Hong Kong (NCT01353742)
  • 28 Feb 2011 Phase-I clinical trials in Hepatitis B in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top